

In the claims:

Please cancel [✓]claims 1-16.

Please add the following claims:

17. (New) A method of inducing a mean ELISA antibody titer of about 1×10^2 against ricin toxin or more in a subject comprising administering to the subject an amount of a deglycosylated ricin A-chain.

18. (New) The method of claim 1, wherein the deglycosylated ricin-A chain is chemically deglycosylated.

19. (New) The method of claim 1, wherein the deglycosylated ricin A-chain is incompletely deglycosylated.

20. (New) The method of claim 19, wherein mannose and fructose are absent from the deglycosylated ricin A-chain.

21. (New) The method of claim 17, wherein the amount is an immunogenic amount.

22. (New) The method of claim 21, wherein the immunogenic amount is about 0.1 μ g to about 10.0 μ g per about 20 g to about 25 g of the weight of the subject.

23. (New) The method of claim 17, wherein two doses an immunogenic amount of a deglycosylated ricin A-chain are administered to the subject.

24. (New) The method of claim 17, further comprising administering an adjuvant to the subject.

25. (New) A method for providing neutralizing antibodies against ricin toxin or preventing ricin intoxication in a subject comprising administering at least two doses of an immunogenic amount of a chemically deglycosylated ricin A-chain to the subject.

Q2

09560315-092401
104260-57E09560

26. (New) The method of claim 25, wherein the chemically deglycosylated ricin A-chain is incompletely deglycosylated.

27. (New) The method of claim 26, wherein mannose and fructose are absent from the chemically deglycosylated ricin A-chain.

28. (New) A vaccine against ricin intoxication comprising a chemically deglycosylated ricin A-chain in an immunogenic amount, wherein the immunogenic amount of the chemically deglycosylated ricin A-chain provides a mean ELISA antibody titer of about 1×10^2 or more in a subject.

29. (New) The vaccine of claim 28, wherein the chemically deglycosylated ricin A-chain is incompletely deglycosylated.

30. (New) The vaccine of claim 28, wherein mannose and fructose are absent from the chemically deglycosylated ricin A-chain.

31. (New) The vaccine of claim 28, wherein two doses of the immunogenic amount of the chemically deglycosylated ricin A-chain provides neutralizing antibodies in a subject.

32. (New) The vaccine of claim 28, wherein two doses of an immunogenic amount of the chemically deglycosylated ricin A-chain prevents ricin intoxication in a subject.

33. (New) A pharmaceutical composition comprising a chemically deglycosylated ricin A-chain in an effective immunogenic amount in a pharmaceutically acceptable carrier and/or adjuvant, wherein the immunogenic amount of the chemically deglycosylated ricin A-chain provides a mean ELISA antibody titer of about 1×10^2 or more in a subject.

Gr
A2

09960315.092401
T04260 STE09660

34. (New) The pharmaceutical composition of claim 33, wherein the chemically deglycosylated ricin A-chain is incompletely deglycosylated.

35. (New) The pharmaceutical composition of claim 33, wherein mannose and fructose are absent from the chemically deglycosylated ricin A-chain.

36. (New) An immunogenic composition comprising, in a physiologically acceptable vehicle, a chemically deglycosylated ricin A-chain, which provides a mean ELISA antibody titer of about 1×10^2 or more in a subject.

37. (New) The immunogenic composition of claim 36, further comprising a adjuvant to enhance the immune response.

38. (New) The immunogenic composition of claim 36, wherein the chemically deglycosylated ricin A-chain is incompletely deglycosylated.

39. (New) The immunogenic composition of claim 36, wherein mannose and fructose are absent from the chemically deglycosylated ricin A-chain.